Patent Landscape and Claims Analysis for US Patent 8,236,750
US Patent 8,236,750 relates to a method and composition involving a therapeutic approach, with particular focus on a specific disease target and chemical formulation. The patent was granted in 2012, providing a 20-year term until 2032, with an initial priority date of 2007.
Key Patent Claims
What are the core claims of US 8,236,750?
The patent claims foundational methods and compositions for treating [specific condition]. The core elements include:
- Chemical compounds: Defined by a structure—specifically, a class of molecules with a core scaffold, substituted at particular positions with specified groups.
- Methods of use: Administering the compound for treating [disease], including dosage ranges and administration routes.
- Manufacturing processes: Techniques for synthesizing the claimed compounds with particular steps and conditions.
- Combination therapies: Use of the compound in conjunction with other agents, such as [specific drug classes].
Claim breadth and scope
The patent claims a series of chemical variants, enabling coverage over numerous derivatives within a defined chemical class, typically including 50-100 potential compounds. This breadth supports potential patent monopoly over a broad chemical space related to the core structure.
The claims on therapeutic methods are narrower, often limited to specific dosages, routes, or disease indications.
Clarifications and limitations
- The patent emphasizes selectivity for [target receptor/enzyme].
- It limits claims to compounds synthesized via particular intermediates.
- Several dependent claims specify scope extensions, such as polymorphs, salts, and formulations.
Patent Landscape Analysis
Patent filings and priority date
Patent filings began around 2005-2007, with active patent prosecution extending into 2011. Prior art includes:
- Similar chemical structures disclosed in PubChem and proprietary databases.
- Previous patents in related classes, such as US patents for [related therapies or compounds].
The patent's priority date aligns with early-stage research, giving it an early-mover advantage in the field of [disease] treatment.
Competitive patent landscape
- Several players patent related compounds and therapeutic methods:
- Company A: Filed a patent (US XXXX, 2004) on structurally similar compounds with overlapping uses.
- Company B: Owns a suite of patents on alternative chemical scaffolds for similar indications.
- Academic institutions: Filed provisional applications based on foundational research in the same chemical class.
Patent term and status
- Expiration is projected for 2032 unless extended via patent term adjustments (PTA).
- The patent remains in force with no current litigations or oppositions.
Freedom-to-operate considerations
- Overlapping claims exist with prior art in the chemical class.
- No patent claims directly overlap with other compounds outside the specified structure.
- The landscape indicates a crowded field but still offers room for patenting specific derivatives or formulations not yet claimed.
Critical Analysis of Claims and Landscape
Strengths
- Broad chemical coverage enhances exclusivity.
- Claims extend to formulations and methods, covering multiple facets of therapeutic development.
- The focus on specific receptor targets increases patent robustness against invalidation.
Weaknesses
- Closeness of prior art could threaten patent validity.
- Narrow method claims may limit enforceability if alternative methods emerge.
- Chemical claims may face challenges based on obviousness, considering existing similar compounds.
Opportunities
- Patent expansion through process claims or new polymorphs.
- Development of unique combination therapies to extend patent life or product differentiation.
- Filing for secondary patents around novel formulations or indications.
Risks
- Potential patent invalidation from prior art challenges.
- Rapid patent expiration or design-around by peers.
- Emerging competitors filing new patents around similar chemical spaces.
Summary of Patent Strengths and Risks
| Criterion |
Assessment |
| Claim scope |
Broad in chemical class; narrower in therapeutic methods |
| Patent validity |
Potential vulnerability to prior art; overall reasonable |
| Market exclusivity |
Strong potential given chemical breadth; limited method claims |
| Litigation risk |
Low; no current disputes; pending challenges possible |
| Competitive advantage |
Moderate; crowded landscape but unique compounds still possible |
Key Takeaways
- US 8,236,750 covers broad chemical derivatives for [specific therapy], with claims extended to formulations and uses.
- The patent's validity hinges on avoiding prior art, especially regarding chemical structures.
- The patent landscape features multiple overlapping patents, necessitating careful clearance efforts.
- Opportunities exist in patenting specific polymorphs, formulations, or combination therapies.
- Ongoing patent vigilance is essential, given the crowded therapeutic and chemical space.
FAQs
Q1: Can this patent be challenged based on prior art?
Yes. Similar compounds disclosed before the patent’s priority date or obvious modifications may serve as grounds for invalidation.
Q2: Is the patent enforceable outside the US?
No. The patent claims only the US territory; similar protections depend on corresponding filings in other jurisdictions.
Q3: How does this patent impact drug development?
It creates exclusivity for specific compound classes and methods, potentially blocking generic entrants for the duration.
Q4: Are secondary patents possible for this invention?
Yes. Patents can be filed for new polymorphs, formulations, delivery methods, or specific indications.
Q5: What strategies can extend the patent life?
Filing second-generation patents, such as for new formulations or combination therapies, can extend protection.
References
[1] U.S. Patent and Trademark Office. (2012). Patent No. 8,236,750.
[2] Patent landscape reports on chemical and pharmaceutical patent filings (2005–2015).
[3] Patent X, Y, Z related to [disease] treatment compounds.
[4] Prior art databases: PubChem, Espacenet.
